Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001193125-26-209100
Filing Date
2026-05-06
Accepted
2026-05-06 16:26:24
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 22368
2 EX-99.1 ormp-ex99_1.pdf EX-99.1 80930
  Complete submission text file 0001193125-26-209100.txt   135676
Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund XII, L.P. (Filed by) CIK: 0001906837 (see all company filings)

EIN.: 873448430 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D

Mailing Address 6 TIDE STREET SUITE 400 BOSTON MA 02110
Business Address 6 TIDE STREET SUITE 400 BOSTON MA 02110 617-807-4062
Seaport Therapeutics, Inc. (Subject) CIK: 0002042347 (see all company filings)

EIN.: 992235719 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-95656 | Film No.: 26948910
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)